Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CADL vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CADL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

CADL Overall Winner 6-Pillar Tally: CADL 3 – 2 EVMN (1 Tie) Matrix Metrics: CADL 5 – 2 EVMN

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CADL carries a Unified Composite Score of 47.4/100 (HOLD) at $5.81 (43.5x Forward P/E, 0.0% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CADL vs EVMN
CADL NASDAQ Head-to-Head Winner
Candel Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$5.81
-6.29% 1D
Market Cap $486.4M
TTM Revenue $31,000
Forward P/E 43.5x
Beta / 30D Vol 2.12β · 125% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $8.33 · SMA50: $9.62
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (CADL 3 – 2 EVMN)

Columns: Metric · CADL · EVMN
1. Valuation Multiples CADL
Forward P/E 43.5x N/M
Trailing P/E 43.5x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CADL
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31,000 N/A
Market Cap $486.4M $315.5M
3. Profitability & Quality EVMN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.7% -69.5%
4. Balance Sheet & Cash Flow CADL
Cash Generation (TTM) -$57M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $152M Net Cash $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 115.4% (24th %ile) 209.0% (53rd %ile)
Put/Call OI Skew 0.50x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CADL (5) vs EVMN (2)
Institutional Metric CADL EVMN Criterion Row Edge
Market Capitalization
Scale
$486.4M $315.5M Larger Scale CADL
Trailing P/E Ratio
Valuation
43.5x N/M Lower Multiple CADL
Forward P/E Ratio
Valuation
43.5x N/M Lower Multiple CADL
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.7% -69.5% Higher ROE EVMN
52-Week Range Position
Momentum
15% ($4–$14) 8% ($5–$33) Stronger Trend CADL
Beta / 30D Volatility
Risk Regime
2.12β · 125% Vol 1.05β · 118% Vol Lower Realized Risk EVMN
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite CADL
Trailing 12M Revenue (USD)
Operating Scale
$31,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$57M ($152M Net Cash) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +66.39 pp
CADL: -29.06% · EVMN: +37.33%
3M Horizon EVMN +1.71 pp
CADL: -51.78% · EVMN: -50.07%
6M Horizon CADL +41.11 pp
CADL: -26.46% · EVMN: -67.57%
1Y Horizon CADL +87.06 pp
CADL: +26.03% · EVMN: -61.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CADL Revenue EVMN Revenue CADL Op. Margin EVMN Op. Margin Margin Leader
FY2020 $0M N/A -11048.0% N/A CADL
FY2021 $0M N/A -20580.8% N/A CADL
FY2022 $0M N/A -27777.6% N/A CADL
FY2024 N/A $10M N/A -1000.2% EVMN
FY2025 N/A $10M N/A -623.6% EVMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CADL BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 115.4%
IV Percentile 24th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CADL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CADL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $486.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CADL vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CADL carries a Unified Composite Score of 47.4/100 (HOLD) at $5.81 (43.5x Forward P/E, 0.0% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CADL leads the Growth & Scale pillar: CADL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $31,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 5-period historical trajectory (FY2020 to FY2025), CADL cumulative revenue shifted N/A while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, CADL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

CADL screens cheaper on headline valuation multiples. CADL trades at 43.5x Forward P/E, 43.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CADL (-93.7% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CADL carries 115.4% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.12β · 125% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.